{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:14Z","timestamp":1753891994287,"version":"3.41.2"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphoma is a heterogeneous group of tumors in terms of morphological subtypes, molecular alterations, and management. However, data on circulating tumor DNA (ctDNA) mutated genes are limited. The purpose of this study was to investigate the features of the ctDNA mutated genes, the prognosis, and the association between the ctDNA mutated genes and the clinical parameters in lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Differences in the ctDNA between the mutated genes and the prognosis of 59 patients with Hodgkin\u2019s lymphoma (HL) (10.2%), germinal center B-cell\u2013like lymphoma (GCB) (28.8%), nongerminal center B-cell\u2013like lymphoma (non-GCB) (50.8%), and marginal zone lymphoma (MZL) (10.2%) were analyzed by next generation sequencing (NGS) targeting 121 lymphoma-relevant genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Genetic alterations were identified in the ctDNA samples with a median of 6 variants per sample. The genetic variation of the ctDNA in the plasma was found to be significantly correlated with the clinical indices in lymphoma. The genetic heterogeneity of different lymphoma subtypes was clearly observed in the ctDNAs from HL, GCB, non-GCB, and MZL, confirming that distinct molecular mechanisms are involved in the pathogenesis of different lymphomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that NGS-based ctDNA mutation analysis reveals genetic heterogeneity across lymphoma subtypes, with potential implications for discovering therapeutic targets, exploring genomic evolution, and developing risk-adaptive therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.901547","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T06:25:57Z","timestamp":1657002357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Tumor DNA Characteristics Based on Next Generation Sequencing and Its Correlation With Clinical Parameters in Patients With Lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiao-Bo","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ling","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Shui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.001","article-title":"Hodgkin's Lymphoma: The Hazards of Success","volume":"21","author":"Connors","year":"2003","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse Large B-Cell Lymphoma (DLBCL): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of Risk Factors on Outcomes in Early-Stage Hodgkin's Lymphoma: An Analysis of International Staging Definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-467X.2006.08.017","article-title":"Feasibility Study of Application of International Prognostic Score on Prediction of Prognosis for Advanced Hodgkin's Lymphoma","volume":"25","author":"Fu","year":"2006","journal-title":"Ai Zheng"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0650-x","article-title":"Outcome in Patients With Diffuse Large B-Cell Lymphoma Who Relapse After Autologous Stem Cell Transplantation and Receive Active Therapy. A Retrospective Analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"55","author":"Gonz\u00e1lez-Barca","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000475530","article-title":"Tumor Heterogeneity in Lymphomas: A Different Breed","volume":"85","author":"Sch\u00fcrch","year":"2018","journal-title":"Pathobiology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41698-017-0039-5","article-title":"The Potential of Liquid Biopsies for the Early Detection of Cancer","volume":"1","author":"Heitzer","year":"2017","journal-title":"NPJ Precis Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S141991","article-title":"Review of the Clinical Applications and Technological Advances of Circulating Tumor DNA in Cancer Monitoring","volume":"13","author":"Chang","year":"2017","journal-title":"Ther Clin Risk Manage"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112665","article-title":"Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL","volume":"13","author":"Baraniskin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","article-title":"Validation of a Liquid Biopsy Assay With Molecular and Clinical Profiling of Circulating Tumor DNA","volume":"5","author":"Finkle","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-020-0459-7","article-title":"Reliability of Liquid Biopsy Analysis: An Inter-Laboratory Comparison of Circulating Tumor DNA Extraction and Sequencing With Different Platforms","volume":"100","author":"Koessler","year":"2020","journal-title":"Lab Inv J Tech Methods Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.289629","article-title":"Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing","volume":"64","author":"Mansukhani","year":"2018","journal-title":"Clin Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-32","article-title":"Earlier Extracranial Progression and Shorter Survival in ALK-Rearranged Lung Cancer With Positive Liquid Rebiopsies","volume":"10","author":"Christopoulos","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and Detection of Low-Allele-Fraction Variants in Clinical Cancer Samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/0471250953.bi1504s44","article-title":"Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection","volume":"44","author":"Koboldt","year":"2013","journal-title":"Curr Protoc Bioinf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.10.004","article-title":"Applications and Analysis of Targeted Genomic Sequencing in Cancer Studies","volume":"17","author":"Bewicke-Copley","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2022.42.2.141","article-title":"Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing","volume":"42","author":"Shin","year":"2022","journal-title":"Ann Lab Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.292318","article-title":"Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies","volume":"64","author":"Zavridou","year":"2018","journal-title":"Clin Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.835727","article-title":"Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte(\u00ae) Platform","volume":"13","author":"Kaldjian","year":"2022","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 Updated WHO Classification of Lymphoid Neoplasias","volume":"35","author":"Quintanilla-Martinez","year":"2017","journal-title":"Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","article-title":"TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-Tumorigenic Memory Fate","volume":"182","author":"Venturutti","year":"2020","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2020.1762228","article-title":"TBL1XR1 Mutations in Primary Marginal Zone Lymphomas of Ocular Adnexa Are Associated With Unique Morphometric Phenotypes","volume":"45","author":"Jangam","year":"2020","journal-title":"Curr Eye Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-020-00189-1","article-title":"TBL1XR1 Mutation Predicts Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma Patients","volume":"8","author":"Wang","year":"2020","journal-title":"biomark Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/med.21799","article-title":"MALT1 as a Promising Target to Treat Lymphoma and Other Diseases Related to MALT1 Anomalies","volume":"41","author":"Liang","year":"2021","journal-title":"Med Res Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1999444","article-title":"Targeting MALT1 for the Treatment of Diffuse Large B-Cell Lymphoma","volume":"63","author":"Seshadri","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41419-021-03695-8","article-title":"Genome-Wide CRISPR Screens Reveal Synthetic Lethal Interaction Between CREBBP and EP300 in Diffuse Large B-Cell Lymphoma","volume":"12","author":"Nie","year":"2021","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248886","article-title":"Detection of New Drivers of Frequent B-Cell Lymphoid Neoplasms Using an Integrated Analysis of Whole Genomes","volume":"16","author":"Mosquera Orgueira","year":"2021","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0395","article-title":"Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors","volume":"21","author":"Keddy","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100768","DOI":"10.1016\/j.currproblcancer.2021.100768","article-title":"Inflammatory Myofibroblastic Tumor: Molecular Landscape, Targeted Therapeutics, and Remaining Challenges","volume":"45","author":"Mahajan","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3390\/ijms22052625","article-title":"Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer","volume":"22","author":"Rebuzzi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/cancers13040804","article-title":"Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations","volume":"13","author":"K\u00f6nig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.768913","article-title":"Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma","volume":"12","author":"Elliott","year":"2021","journal-title":"Front Genet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509","article-title":"A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"35349","DOI":"10.1038\/srep35349","article-title":"TRAF3 Deficiency Promotes Metabolic Reprogramming in B Cells","volume":"6","author":"Mambetsariev","year":"2016","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as Anticancer Mechanism: Function and Dysfunction of Its Modulators and Targeted Therapeutic Strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging (Albany N Y)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2305","article-title":"Cancer Epigenetics Reaches Mainstream Oncology","volume":"17","author":"Rodr\u00edguez-Paredes","year":"2011","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: Targeting Epigenetic Marks in Cancer Treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/jpm11121313","article-title":"The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis","volume":"11","author":"Hung","year":"2021","journal-title":"J Personalized Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/cancers13246245","article-title":"Molecular Analysis of Colorectal Cancers Suggests a High Frequency of Lynch Syndrome in Indonesia","volume":"13","author":"Susanti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.3390\/cancers13225698","article-title":"Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors","volume":"13","author":"Larrib\u00e8re","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy061","article-title":"RAS Mutation Analysis in Circulating Tumor DNA From Patients With Metastatic Colorectal Cancer: The AGEO RASANC Prospective Multicenter Study","volume":"29","author":"Bachet","year":"2018","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of Ultra-Rare Mutations by Next-Generation Sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.289629","article-title":"Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing","volume":"64","author":"Mansukhani","year":"2018","journal-title":"Clin Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2016.03.012","article-title":"Comparative Analysis of Circulating Tumor DNA Stability In K(3)EDTA, Streck, and CellSave Blood Collection Tubes","volume":"49","author":"Kang","year":"2016","journal-title":"Clin Biochem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168153","article-title":"The In Vitro Stability of Circulating Tumour DNA","volume":"11","author":"Henao Diaz","year":"2016","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.901547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T06:26:01Z","timestamp":1657002361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.901547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":51,"alternative-id":["10.3389\/fonc.2022.901547"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.901547","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"article-number":"901547"}}